|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:rifampin
gptkb:rifampicin
|
|
gptkbp:activities
|
inhibits RNA synthesis
|
|
gptkbp:approves
|
gptkb:1971
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Rifampin
|
|
gptkbp:can_be_used_with
|
gptkb:ethambutol
gptkb:isoniazid
gptkb:pyrazinamide
|
|
gptkbp:class
|
gptkb:rifamycins
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
active tuberculosis
latent tuberculosis infection
|
|
gptkbp:contraindication
|
porphyria
severe renal impairment
hepatic impairment
hypersensitivity to rifampicin
|
|
gptkbp:dosage_form
|
gptkb:beer
10 mg/kg daily
600 mg daily
|
|
gptkbp:duration
|
6 to 12 months
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:form
|
tablets
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rifadin
|
|
gptkbp:ingredients
|
gptkb:rifampicin
C43 H58 N4 O12
|
|
gptkbp:interacts_with
|
gptkb:warfarin
oral contraceptives
antiretrovirals
|
|
gptkbp:is_atype_of
|
J04 A B02
|
|
gptkbp:is_used_for
|
tuberculosis
|
|
gptkbp:lifespan
|
2 to 5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:marketed_as
|
gptkb:Rifampin
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:products
|
gptkb:rifaximin
rifabutin
rifapentine
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:side_effect
|
nausea
allergic reactions
fever
vomiting
diarrhea
liver damage
rash
flu-like symptoms
red-orange discoloration of urine
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
combination therapy
chemotherapy
antitubercular therapy
|